Skip to main content
OpenTrials

Clinical trial condition

Leukemia, Lymphocytic, Chronic, B-Cell

Explore clinical trials studying Leukemia, Lymphocytic, Chronic, B-Cell. Study availability and eligibility vary by location and protocol.

1,432 public trials 166 recruiting studies
Refine in advanced search Browse all conditions

Leukemia, Lymphocytic, Chronic, B-Cell trial results

Active, Not Recruiting

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT02537613

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • University of Rochester Wilmot Cancer Inst. Rochester, New York, United States
  • Duke University Medical Center Durham, North Carolina, United States
View Trial Details
Active, Not Recruiting

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

NCT02586857

Conditions
Astrocytoma, Chronic Disease, Disease Attributes, +22 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Palo Alto, California, United States
  • Research Site Boston, Massachusetts, United States
  • Research Site Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

NCT02717611

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations
  • Research Site Tucson, Arizona, United States
  • Research Site Concord, California, United States
  • Research Site La Jolla, California, United States
  • Research Site Palo Alto, California, United States
View all 23 locations
View Trial Details
Active, Not Recruiting

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

NCT03534323

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • University of Miami- Sylvester Comprehensive Cancer Center Miami, Florida, United States
  • Northern Light Eastern Maine Medical Center Brewer, Maine, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Boston Medical Center Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

FT819 in Subjects With B-cell Malignancies

NCT04629729

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +20 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Arizona Phoenix, Arizona, United States
  • UC Davis Davis, California, United States
  • Scripps Green Hospital La Jolla, California, United States
View all 18 locations
View Trial Details
Active, Not Recruiting

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

NCT04904588

Conditions
Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, +30 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Stanford University Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 39 locations
View Trial Details
Active, Not Recruiting

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Central Nervous System Lymphoma, +36 more
Locations
  • Cellectar Biosciences site Los Angeles, California, United States
  • Cellectar Biosciences site Redlands, California, United States
  • Cellectar Biosciences site Washington D.C., District of Columbia, United States
  • Cellectar Biosciences site Jacksonville, Florida, United States
View all 52 locations
View Trial Details
Active, Not Recruiting

Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL

NCT05478512

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • Ematologia AOU Careggi Florence, Italy
  • Ematologia IRST D.Amadori Meldola, Italy
  • Ematologia AO di Perugia Perugia, Italy
  • Ematologia Ospedale S.M. delle Croci Ravenna, Italy
View Trial Details

Related conditions